Table 3.

Number of esophageal carcinoma patients with detectable expression of CK20 (CK20+) and DEFA5 (DEFA5+) in blood and bone marrow and their correlation with clinical parameters.

Variable		CK20 + BL (%)	p	DEFA5 + BL (%)	p	CK20 + BM (%)	p	DEFA5 + BM (%)	p
Gender	Male	38 (21.5)	0.40	83 (46.9)	0.51	44 (34.6)	0.39	85 (66.9)	0.86
	Female	9 (28.1)		13 (40.6)		5 (25)		13 (65)
Age [years]	<70	32 (20.6)	0.28	72 (46.5)	0.79	34 (30.9)	0.28	74 (67.3)	0.79
	>70	15 (27.8)		24 (44.4)		15 (40.5)		24 (64.9)
Histotype	AC	35 (22.6)	0.78	70 (45.2)	0.71	39 (34.5)	0.50	78 (69)	0.25
	SCC	12 (22.2)		26 (48.1)		10 (29.4)		20 (58.8)
pT category	T1	12 (22.2)	0.81	29 (53.7)	0.30	12 (33.3)	0.54	23 (63.9)	0.24
	T2	12 (25.5)		21 (44.7)		15 (39.5)		30 (78.9)
	T3	19 (20.9)		38 (41.8)		18 (29)		37 (59.7)
	T4	0		0		0		1 (50)
pN category	N0	25 (24.8)	0.73	52 (51.5)	0.24	22 (31.4)	0.79	49 (70)	0.55
	N1	13 (18.1)		32 (44.4)		19 (38)		32 (64)
	N2	7 (25.9)		10 (37)		7 (31.8)		15 (68.2)
	N3	2 (22.2)		2 (22.2)		1 (20)		2 (40)
pM category	M0	45 (23.2)	0.38	88 (45.4)	0.55	47 (34.6)	0.27	91 (66.9)	0.82
	M1	2 (13.3)		8 (53.3)		2 (18.2)		7 (63.6)
UICC stage	I	11 (23.4)	0.91	27 (57.4)	0.30	11 (35.5)	0.91	21 (67.7)	0.79
	II	10 (20)		21 (42)		12 (32.4)		26 (70.3)
	III	18 (24)		31 (41.3)		18 (33.3)		35 (64.8)
	IV	4 (18.2)		9 (40.9)		4 (25)		9 (56.3)
Neoadjuvant therapy	Yes	21 (18.9)	0.19	53 (47.7)	0.57	25 (30.5)	0.41	57 (69.5)	0.41
	No	26 (26.5)		43 (43.9)		24 (36.9)		41 (63.1)
Adjuvant therapy	Yes	8 (14.8)	0.08	21 (38.9)	0.31	13 (31.7)	0.73	32 (78)	0.07
	No	36 (26.9)		63 (47)		32 (34.8)		57 (62)

BL: blood, BM: bone marrow, AD: adenocarcinoma, SCC: squamous cell carcinoma, UICC: Union Internationale Contre le Cancer.